Currently, the primary application of the NMP22 test is in the detection and monitoring of bladder cancer. There is limited evidence to support its use in other types of cancer. Research is ongoing to explore the potential of NMP22 as a biomarker for other cancers, but its effectiveness outside of bladder cancer has not yet been established.
